Technetium Tc 99m tilmanocept for injection
The first and only agent specifically designed for targeted lymphatic mapping and guiding sentinel lymph node biopsy, Lymphoaim® provides accurate and precise lymph node identification enabling onco-surgeons make appropriate decisions in patients with breast cancer, head & neck cancer and melanomas.
Globally the product is approved as Lymphoseek
Awaiting DCGI approval
For more information on LymphoAim®
Please refer https://www.navidea.com/ or contact your local sales representative or email us at info@sayretherapeutics.com
Tilmanocept (Lymphoaim)
Lymphoaim® (Tilmanocept) is the first and only radiopharmaceutical agent specifically designed for targeted lymphatic mapping and guiding sentinel lymph node biopsy. Lymphoaim® provides accurate and precise lymph node identification enabling onco-surgeons make appropriate decisions in patients with breast cancer, head & neck cancer and melanomas.
“
